Westpac Banking Corp Purchases 4,030 Shares of Eli Lilly and Company $LLY

Westpac Banking Corp boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 39.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,222 shares of the company’s stock after acquiring an additional 4,030 shares during the period. Eli Lilly and Company comprises approximately 1.0% of Westpac Banking Corp’s investment portfolio, making the stock its 14th biggest holding. Westpac Banking Corp’s holdings in Eli Lilly and Company were worth $15,284,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after buying an additional 1,006,885 shares during the last quarter. State Street Corp boosted its stake in Eli Lilly and Company by 0.6% during the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after buying an additional 219,590 shares during the last quarter. Capital Research Global Investors boosted its stake in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Wellington Management Group LLP boosted its stake in Eli Lilly and Company by 4.1% during the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after buying an additional 574,229 shares during the last quarter. Finally, Norges Bank bought a new position in Eli Lilly and Company during the fourth quarter valued at approximately $12,976,634,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,064.52 on Wednesday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,149.10. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a market capitalization of $1.00 trillion, a P/E ratio of 37.82, a P/E/G ratio of 1.18 and a beta of 0.53. The stock has a 50 day moving average price of $959.18 and a 200 day moving average price of $1,010.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the company earned $3.34 EPS. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a research note on Tuesday, February 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,227.00.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s obesity franchise got a major boost as CVS Caremark and the other two largest U.S. PBMs now cover its full obesity portfolio, including Zepbound and the newly approved oral drug Foundayo, widening access and improving the growth outlook. Article Title
• Positive Sentiment: The company is signaling a bigger M&A push, with its top dealmaker saying Lilly may use GLP-1 profits to fund acquisitions in new therapeutic areas, which could diversify the pipeline and reduce dependence on obesity drugs. Article Title
• Positive Sentiment: Lilly continues to deepen its pipeline through licensing and acquisition activity, including deals tied to next-gen vaccines, intestinal disease treatment, and cardiometabolic drugs, reinforcing long-term growth expectations. Article Title
• Positive Sentiment: Recent clinical updates were also favorable, including positive Retevmo data in lung cancer and expanded attention on Lilly’s hematology portfolio ahead of the EHA meeting, supporting confidence in the non-obesity pipeline. Article Title
• Neutral Sentiment: Lilly also issued a tougher stance toward 340B hospitals, demanding claims data or risking lost discounts; this could pressure provider relationships even though it may help pricing discipline. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.